DRUG · Unmapped registry intervention
PLD Chemotherapy
Find medicine records ·
Find other trials using this name
Clinical trial
CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
NCT05029999
Drugs and interventions used in this trial
3 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Unmapped registry intervention
CDX-1140
Find medicine records ·
Find other trials using this name
DRUG · Unmapped registry intervention
CDX-301
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedCD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE1
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
HER2-negative Breast Cancerunresolved
Metastatic Breast Cancerunresolved
Interventions
Sponsors & collaborators
University of Texas Southwestern Medical Centerlead sponsor
Celldex Therapeuticscollaborator
Gateway for Cancer Researchcollaborator
National Cancer Institute (NCI)collaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05029999 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.